Antibody-drug conjugates comprising anti-B7-H3 antibodies
US12168060B2 · kind B2 · utility
0Cited by
1References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 25, 2021 |
| Grant date | Dec 17, 2024 |
| Priority date | — |
| Expiry date | Jun 2, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.